Arrowsmith, J. & Miller, P. Trial watch: phase II and phase III attrition rates 2011-2012. Nat. Rev. Drug Discov. 12, 569 (2013).
Google Scholar
Harrison, R. K. Phase II and phase III failures: 2013-2015. Nat. Rev. Drug Discov. 15, 817–818 (2016).
Google Scholar
Wouters, O. J., McKee, M. & Luyten, J. Estimated research and development investment needed to bring a new medicine to market, 2009-2018. JAMA 323, 844–853 (2020).
Google Scholar
Cook, D. et al. Lessons learned from the fate of AstraZeneca’s drug pipeline: a five-dimensional framework. Nat. Rev. Drug Discov. 13, 419–431 (2014).
Google Scholar
Razuvayevskaya, O., Lopez, I., Dunham, I. & Ochoa, D. Why clinical trials stop: the role of genetics. Preprint at medRxiv https://doi.org/10.1101/2023.02.07.23285407 (2023).
Collins, F. S. Shattuck lecture—Medical and societal consequences of the Human Genome Project. N. Engl. J. Med. 341, 28–37 (1999).
Google Scholar
Lander, E. S. et al. Initial sequencing and analysis of the human genome. Nature 409, 860–921 (2001).
Google Scholar
Venter, J. C. et al. The sequence of the human genome. Science 291, 1304–1351 (2001).
Google Scholar
Spotlight on cancer genomics. Nat. Cancer 1, 265–266 (2020).
Nguengang Wakap, S. et al. Estimating cumulative point prevalence of rare diseases: analysis of the Orphanet database. Eur. J. Hum. Genet. 28, 165–173 (2020).
Google Scholar
Abdellaoui, A., Yengo, L., Verweij, K. J. H. & Visscher, P. M. 15 years of GWAS discovery: realizing the promise. Am. J. Hum. Genet. 110, 179–194 (2023).
Google Scholar
Malone, E. R., Oliva, M., Sabatini, P. J. B., Stockley, T. L. & Siu, L. L. Molecular profiling for precision cancer therapies. Genome Med. 12, 8 (2020).
Google Scholar
Waarts, M. R., Stonestrom, A. J., Park, Y. C. & Levine, R. L. Targeting mutations in cancer. J. Clin. Invest. 132, e154943 (2022).
Google Scholar
Sabatine, M. S. et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N. Engl. J. Med. 372, 1500–1509 (2015).
Google Scholar
Hall, S. S. Genetics: a gene of rare effect. Nature 496, 152–155 (2013).
Google Scholar
Abifadel, M. et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat. Genet. 34, 154–156 (2003).
Google Scholar
Zhao, Z. et al. Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote. Am. J. Hum. Genet. 79, 514–523 (2006).
Google Scholar
Cohen, J. C., Boerwinkle, E., Mosley, T. H. Jr. & Hobbs, H. H. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N. Engl. J. Med. 354, 1264–1272 (2006). To our knowledge, refs. 16–18 provided the first genetic rationale for the discovery and development of PCKS9 inhibitors as a safe way to treat familial hypercholesterolemia and coronary artery disease.
Google Scholar
Raedler, L. A. Praluent (alirocumab): first PCSK9 inhibitor approved by the FDA for hypercholesterolemia. Am. Health Drug Benefits 9, 123–126 (2016).
Google Scholar
King, E. A., Davis, J. W. & Degner, J. F. Are drug targets with genetic support twice as likely to be approved? Revised estimates of the impact of genetic support for drug mechanisms on the probability of drug approval. PLoS Genet. 15, e1008489 (2019).
Google Scholar
Nelson, M. R. et al. The support of human genetic evidence for approved drug indications. Nat. Genet. 47, 856–860 (2015). References 20,21 demonstrated retrospectively that genetically supported targets are more likely to lead to approved therapies.
Google Scholar
Ochoa, D. et al. Human genetics evidence supports two-thirds of the 2021 FDA-approved drugs. Nat. Rev. Drug Discov. 21, 551 (2022).
Google Scholar
Seidah, N. G. The PCSK9 revolution and the potential of PCSK9-based therapies to reduce LDL-cholesterol. Glob. Cardiol. Sci. Pract. 2017, e201702 (2017).
Google Scholar
Ochoa, D. et al. The next-generation Open Targets Platform: reimagined, redesigned, rebuilt. Nucleic Acids Res. 51, D1353–D1359 (2022).
Google Scholar
Wishart, D. S. et al. DrugBank: a comprehensive resource for in silico drug discovery and exploration. Nucleic Acids Res. 34, D668–672 (2006).
Google Scholar
Sparrow, A. J., Watkins, H., Daniels, M. J., Redwood, C. & Robinson, P. Mavacamten rescues increased myofilament calcium sensitivity and dysregulation of Ca2+ flux caused by thin filament hypertrophic cardiomyopathy mutations. Am. J. Physiol. Heart. Circ. Physiol. 318, H715–h722 (2020).
Google Scholar
Watkins, H., Ashrafian, H. & Redwood, C. Inherited cardiomyopathies. N. Engl. J. Med. 364, 1643–1656 (2011).
Google Scholar
Toepfer, C. N. et al. Myosin sequestration regulates sarcomere function, cardiomyocyte energetics, and metabolism, informing the pathogenesis of hypertrophic cardiomyopathy. Circulation 141, 828–842 (2020).
Google Scholar
Santos, R. et al. A comprehensive map of molecular drug targets. Nat. Rev. Drug Discov. 16, 19–34 (2017).
Google Scholar
Brinkman, R. R., Dube, M. P., Rouleau, G. A., Orr, A. C. & Samuels, M. E. Human monogenic disorders—a source of novel drug targets. Nat. Rev. Genet. 7, 249–260 (2006).
Google Scholar
Desnick, R. J. & Schuchman, E. H. Enzyme replacement therapy for lysosomal diseases: lessons from 20 years of experience and remaining challenges. Annu. Rev. Genomics Hum. Genet. 13, 307–335 (2012).
Google Scholar
Yang, H. et al. Nanomolar affinity small molecule correctors of defective Delta F508-CFTR chloride channel gating. J. Biol. Chem. 278, 35079–35085 (2003).
Google Scholar
Van Goor, F. et al. Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770. Proc. Natl Acad. Sci. USA 106, 18825–18830 (2009).
Google Scholar
RNAi therapeutics market: growing investments in RNAi therapies. BioSpace https://www.biospace.com/article/rnai-therapeutics-market-growing-investments-in-rnai-therapies/ (2021).
Kim, J. et al. Patient-customized oligonucleotide therapy for a rare genetic disease. N. Engl. J. Med. 381, 1644–1652 (2019).
Google Scholar
European Medicines Agency recommends first gene therapy for approval. European Medicines Agency https://www.ema.europa.eu/en/news/european-medicines-agency-recommends-first-gene-therapy-approval (2012).
Ribeil, J. A. et al. Gene therapy in a patient with sickle cell disease. N. Engl. J. Med. 376, 848–855 (2017).
Google Scholar
Esrick, E. B. et al. Post-transcriptional genetic silencing of BCL11A to treat sickle cell disease. N. Engl. J. Med. 384, 205–215 (2021).
Google Scholar
Thompson, A. A. et al. Gene therapy in patients with transfusion-dependent beta-thalassemia. N. Engl. J. Med. 378, 1479–1493 (2018).
Google Scholar
Li, H. et al. Applications of genome editing technology in the targeted therapy of human diseases: mechanisms, advances and prospects. Signal Transduct. Target. Ther. 5, 1 (2020).
Google Scholar
Frangoul, H. et al. CRISPR–Cas9 gene editing for sickle cell disease and beta-thalassemia. N. Engl. J. Med. 384, 252–260 (2021).
Google Scholar
Dean, M. et al. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study. Science 273, 1856–1862 (1996).
Google Scholar
Samson, M. et al. Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 382, 722–725 (1996).
Google Scholar
FDA approves maraviroc tablets. AIDS Patient Care STDs 21, 702 (2007).
Piters, E. et al. First missense mutation in the SOST gene causing sclerosteosis by loss of sclerostin function. Hum. Mutat. 31, E1526–E1543 (2010).
Google Scholar
Balemans, W. et al. Identification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease. J. Med. Genet. 39, 91–97 (2002).
Google Scholar
Musunuru, K. et al. Exome sequencing, ANGPTL3 mutations, and familial combined hypolipidemia. N. Engl. J. Med. 363, 2220–2227 (2010).
Google Scholar
Martin-Campos, J. M. et al. Identification of a novel mutation in the ANGPTL3 gene in two families diagnosed of familial hypobetalipoproteinemia without APOB mutation. Clin. Chim. Acta 413, 552–555 (2012).
Google Scholar
Romeo, S. et al. Rare loss-of-function mutations in ANGPTL family members contribute to plasma triglyceride levels in humans. J. Clin. Invest. 119, 70–79 (2009).
Google Scholar
Mullard, A. FDA approves first anti-ANGPTL3 antibody, for rare cardiovascular indication. Nat. Rev. Drug Discov. 20, 251 (2021).
Google Scholar
Banerjee, Y. et al. Inclisiran: a small interfering RNA strategy targeting PCSK9 to treat hypercholesterolemia. Expert Opin. Drug Saf. 21, 9–20 (2022).
Google Scholar
Wang, L. et al. Long-term stable reduction of low-density lipoprotein in nonhuman primates following in vivo genome editing of PCSK9. Mol. Ther. 29, 2019–2029 (2021).
Google Scholar
Musunuru, K. et al. In vivo CRISPR base editing of PCSK9 durably lowers cholesterol in primates. Nature 593, 429–434 (2021).
Google Scholar
Reyes-Soffer, G. et al. Lipoprotein(a): a genetically determined, causal, and prevalent risk factor for atherosclerotic cardiovascular disease: a scientific statement from the American Heart Association. Arterioscler. Thromb. Vasc. Biol. 42, e48–e60 (2022).
Google Scholar
Tsimikas, S. et al. Lipoprotein(a) reduction in persons with cardiovascular disease. N. Engl. J. Med. 382, 244–255 (2020).
Google Scholar
Yeang, C. et al. Effect of pelacarsen on lipoprotein(a) cholesterol and corrected low-density lipoprotein cholesterol. J. Am. Coll. Cardiol. 79, 1035–1046 (2022).
Google Scholar
Koren, M. J. et al. Preclinical development and phase 1 trial of a novel siRNA targeting lipoprotein(a). Nat. Med. 28, 96–103 (2022).
Google Scholar
Mendonca, B. B. et al. Steroid 5α-reductase 2 deficiency. J. Steroid Biochem. Mol. Biol. 163, 206–211 (2016).
Google Scholar
Gormley, G. J. et al. The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group. N. Engl. J. Med. 327, 1185–1191 (1992).
Google Scholar
Kaufman, K. D. et al. Finasteride in the treatment of men with androgenetic alopecia. Finasteride Male Pattern Hair Loss Study Group. J. Am. Acad. Dermatol. 39, 578–589 (1998).
Google Scholar
Rafiq, M. et al. Effective treatment with oral sulfonylureas in patients with diabetes due to sulfonylurea receptor 1 (SUR1) mutations. Diabetes Care 31, 204–209 (2008).
Google Scholar
Savarirayan, R. et al. Infigratinib in children with achondroplasia: the PROPEL and PROPEL 2 studies. Ther. Adv. Musculoskelet. Dis. 14, 1759720×221084848 (2022).
Google Scholar
Duerr, R. H. et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 314, 1461–1463 (2006).
Google Scholar
Wellcome Trust Case Control Consortium. Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants. Nat. Genet. 39, 1329–1337 (2007).
Google Scholar
Mokry, L. E. et al. Interleukin-18 as a drug repositioning opportunity for inflammatory bowel disease: a Mendelian randomization study. Sci. Rep. 9, 9386 (2019).
Google Scholar
Niemi, M. E. K. et al. Mapping the human genetic architecture of COVID-19. Nature 600, 472–477 (2021).
Google Scholar
RECOVERY Collaborative Group. Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis. Lancet 400, 1102 (2022).
Tishkoff, S. A. & Verrelli, B. C. Patterns of human genetic diversity: implications for human evolutionary history and disease. Annu. Rev. Genomics Hum. Genet. 4, 293–340 (2003).
Google Scholar
Slatkin, M. A population-genetic test of founder effects and implications for Ashkenazi Jewish diseases. Am. J. Hum. Genet. 75, 282–293 (2004).
Google Scholar
de la Chapelle, A. Disease gene mapping in isolated human populations: the example of Finland. J. Med. Genet. 30, 857–865 (1993).
Google Scholar
Kurki, M. I. et al. FinnGen provides genetic insights from a well-phenotyped isolated population. Nature 613, 508–518 (2023).
Google Scholar
Moises, H. W. et al. An international two-stage genome-wide search for schizophrenia susceptibility genes. Nat. Genet. 11, 321–324 (1995).
Google Scholar
Spedicati, B. et al. Natural human knockouts and Mendelian disorders: deep phenotyping in Italian isolates. Eur. J. Hum. Genet. 29, 1272–1281 (2021).
Google Scholar
Baskovich, B. et al. Expanded genetic screening panel for the Ashkenazi Jewish population. Genet. Med. 18, 522–528 (2016).
Google Scholar
Bherer, C. et al. Admixed ancestry and stratification of Quebec regional populations. Am. J. Phys. Anthropol. 144, 432–441 (2011).
Google Scholar
Laberge, A. M. et al. Population history and its impact on medical genetics in Quebec. Clin. Genet. 68, 287–301 (2005).
Google Scholar
Locke, A. E. et al. Exome sequencing of Finnish isolates enhances rare-variant association power. Nature 572, 323–328 (2019).
Google Scholar
Erzurumluoglu, A. M., Shihab, H. A., Rodriguez, S., Gaunt, T. R. & Day, I. N. Importance of genetic studies in consanguineous populations for the characterization of novel human gene functions. Ann. Hum. Genet. 80, 187–196 (2016).
Google Scholar
Minikel, E. V. et al. Evaluating drug targets through human loss-of-function genetic variation. Nature 581, 459–464 (2020). This analysis provides a comprehensive roadmap for human knockout studies to discover relevant loss-of-function variants that can guide drug discovery and development.
Google Scholar
Saleheen, D. et al. Human knockouts and phenotypic analysis in a cohort with a high rate of consanguinity. Nature 544, 235–239 (2017).
Google Scholar
Lu, T. et al. Individuals with common diseases but with a low polygenic risk score could be prioritized for rare variant screening. Genet. Med. 23, 508–515 (2021).
Google Scholar
Wu, H. et al. Polygenic risk score for low-density lipoprotein cholesterol is associated with risk of ischemic heart disease and enriches for individuals with familial hypercholesterolemia. Circ. Genom. Precis. Med. 14, e003106 (2021).
Google Scholar
Pfizer and Ionis announce discontinuation of vupanorsen clinical development program. CISION https://www.prnewswire.com/news-releases/pfizer-and-ionis-announce-discontinuation-of-vupanorsen-clinical-development-program-301471041.html (2022).
Kingwell, K. Double setback for ASO trials in Huntington disease. Nat. Rev. Drug Discov. 20, 412–413 (2021).
Google Scholar
Romeo, S. et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat. Genet. 40, 1461–1465 (2008).
Google Scholar
Yuan, X. et al. Population-based genome-wide association studies reveal six loci influencing plasma levels of liver enzymes. Am. J. Hum. Genet. 83, 520–528 (2008).
Google Scholar
Davey Smith, G. & Hemani, G. Mendelian randomization: genetic anchors for causal inference in epidemiological studies. Hum. Mol. Genet. 23, R89–98 (2014).
Google Scholar
Gill, D. et al. Mendelian randomization for studying the effects of perturbing drug targets. Wellcome Open Res. 6, 16 (2021).
Google Scholar
Ference, B. A. Mendelian randomization studies: using naturally randomized genetic data to fill evidence gaps. Curr. Opin. Lipidol. 26, 566–571 (2015).
Google Scholar
Schmidt, A. F. et al. Genetic drug target validation using Mendelian randomisation. Nat. Commun. 11, 3255 (2020). This study provides an analytical framework on how to utilize Mendelian randomization for drug target validation.
Google Scholar
Zheng, J. et al. Phenome-wide Mendelian randomization mapping the influence of the plasma proteome on complex diseases. Nat. Genet. 52, 1122–1131 (2020).
Google Scholar
Ferkingstad, E. et al. Large-scale integration of the plasma proteome with genetics and disease. Nat. Genet. 53, 1712–1721 (2021). This article depicts in great depth the largest genome-wide association studies of plasma protein levels to date and describes 938 genes encoding potential drug targets with variants that influence levels of protein biomarkers.
Google Scholar
Miller, C. L. et al. Integrative functional genomics identifies regulatory mechanisms at coronary artery disease loci. Nat. Commun. 7, 12092 (2016).
Google Scholar
Ganesan, A., Arimondo, P. B., Rots, M. G., Jeronimo, C. & Berdasco, M. The timeline of epigenetic drug discovery: from reality to dreams. Clin. Epigenetics 11, 174 (2019).
Google Scholar
Steinberg, J. et al. Integrative epigenomics, transcriptomics and proteomics of patient chondrocytes reveal genes and pathways involved in osteoarthritis. Sci. Rep. 7, 8935 (2017).
Google Scholar
Spreafico, R., Soriaga, L. B., Grosse, J., Virgin, H. W. & Telenti, A. Advances in genomics for drug development. Genes 11, 942 (2020).
Google Scholar
Zhou, S. et al. A Neanderthal OAS1 isoform protects individuals of European ancestry against COVID-19 susceptibility and severity. Nat. Med. 27, 659–667 (2021).
Google Scholar
Yoshiji, S. et al. Proteome-wide Mendelian randomization implicates nephronectin as an actionable mediator of the effect of obesity on COVID-19 severity. Nat. Metab. 5, 248–264 (2023).
Google Scholar
Carss, K. J. et al. Using human genetics to improve safety assessment of therapeutics. Nat. Rev. Drug Discov. 22, 145–162 (2023). This review discusses how genetics can be used to anticipate potential safety issues associated with a particular drug target and to de-risk clinical development.
Google Scholar
Diogo, D. et al. TYK2 protein-coding variants protect against rheumatoid arthritis and autoimmunity, with no evidence of major pleiotropic effects on non-autoimmune complex traits. PLoS ONE 10, e0122271 (2015).
Google Scholar
Marx, V. The DNA of a nation. Nature 524, 503–505 (2015).
Google Scholar
100,000 Genomes Project Pilot Investigators. 100,000 Genomes Pilot on Rare-Disease Diagnosis in Health Care—preliminary report. N. Engl. J. Med. 385, 1868–1880 (2021).
Google Scholar
Turnbull, C. Introducing whole-genome sequencing into routine cancer care: the Genomics England 100,000 Genomes Project. Ann. Oncol. 29, 784–787 (2018).
Google Scholar
Kousathanas, A. et al. Whole-genome sequencing reveals host factors underlying critical COVID-19. Nature 607, 97–103 (2022).
Google Scholar
Bycroft, C. et al. The UK Biobank resource with deep phenotyping and genomic data. Nature 562, 203–209 (2018).
Google Scholar
Sankar, P. L. & Parker, L. S. The Precision Medicine Initiative’s All of Us research program: an agenda for research on its ethical, legal, and social issues. Genet. Med. 19, 743–750 (2017).
Google Scholar
Gudbjartsson, D. F. et al. Large-scale whole-genome sequencing of the Icelandic population. Nat. Genet. 47, 435–444 (2015).
Google Scholar
Sakaue, S. et al. A cross-population atlas of genetic associations for 220 human phenotypes. Nat. Genet. 53, 1415–1424 (2021). This study provides an atlas of up to 220 genotype–phenotype associations in non-Europeans that enriches the field with data from diverse populations.
Google Scholar
Nagai, A. et al. Overview of the BioBank Japan Project: study design and profile. J. Epidemiol. 27, S2–s8 (2017).
Google Scholar
Leitsalu, L. et al. Cohort profile: Estonian Biobank of the Estonian Genome Center, University of Tartu. Int. J. Epidemiol. 44, 1137–1147 (2014).
Google Scholar
Gharahkhani, P. et al. Genome-wide meta-analysis identifies 127 open-angle glaucoma loci with consistent effect across ancestries. Nat. Commun. 12, 1258 (2021).
Google Scholar
Tanigawa, Y. et al. Rare protein-altering variants in ANGPTL7 lower intraocular pressure and protect against glaucoma. PLoS Genet. 16, e1008682 (2020).
Google Scholar
& Akbari, P. et al. Sequencing of 640,000 exomes identifies GPR75 variants associated with protection from obesity. Science 373, eab8683 (2021). This publication reports the discovery of loss-of-function variants in GPR75 and protection from obesity.
Google Scholar
Regeneron Genetics Center discovers GPR75 gene mutations that protect against obesity. Regeneron https://investor.regeneron.com/news-releases/news-release-details/regeneron-genetics-center-discovers-gpr75-gene-mutations-protect (2021).
Abul-Husn, N. S. et al. A protein-truncating HSD17B13 variant and protection from chronic liver disease. N. Engl. J. Med. 378, 1096–1106 (2018).
Google Scholar
Sirugo, G., Williams, S. M. & Tishkoff, S. A. The missing diversity in human genetic studies. Cell 177, 26–31 (2019).
Google Scholar
Martin, A. R. et al. Clinical use of current polygenic risk scores may exacerbate health disparities. Nat. Genet. 51, 584–591 (2019).
Google Scholar
Ramamoorthy, A., Pacanowski, M. A., Bull, J. & Zhang, L. Racial/ethnic differences in drug disposition and response: review of recently approved drugs. Clin. Pharmacol. Ther. 97, 263–273 (2015).
Google Scholar
Gurdasani, D., Barroso, I., Zeggini, E. & Sandhu, M. S. Genomics of disease risk in globally diverse populations. Nat. Rev. Genet. 20, 520–535 (2019).
Google Scholar
Fatumo, S. et al. A roadmap to increase diversity in genomic studies. Nat. Med. 28, 243–250 (2022).
Google Scholar
Popejoy, A. B. & Fullerton, S. M. Genomics is failing on diversity. Nature 538, 161–164 (2016).
Google Scholar
Bien, S. A. et al. The future of genomic studies must be globally representative: perspectives from PAGE. Annu. Rev. Genomics Hum. Genet. 20, 181–200 (2019).
Google Scholar
Wonkam, A. Sequence three million genomes across Africa. Nature 590, 209–211 (2021). This commentary discusses the research benefits of analysing Africa’s genetic variation andsets up a framework to sequence three million African genomes.
Google Scholar
H3Africa Consortium. Research capacity. Enabling the genomic revolution in Africa. Science 344, 1346–1348 (2014).
Google Scholar
Choudhury, A. et al. High-depth African genomes inform human migration and health. Nature 586, 741–748 (2020).
Google Scholar
Wade, K. H. et al. Assessing the causal role of body mass index on cardiovascular health in young adults: Mendelian randomization and recall-by-genotype analyses. Circulation 138, 2187–2201 (2018).
Google Scholar
Corbin, L. J. et al. Metabolic characterisation of disturbances in the APOC3/triglyceride-rich lipoprotein pathway through sample-based recall by genotype. Metabolomics 16, 69 (2020).
Google Scholar
Hellmich, C. et al. Genetics, sleep and memory: a recall-by-genotype study of ZNF804A variants and sleep neurophysiology. BMC Med. Genet. 16, 96 (2015).
Google Scholar
Alver, M. et al. Recall by genotype and cascade screening for familial hypercholesterolemia in a population-based biobank from Estonia. Genet. Med. 21, 1173–1180 (2019).
Google Scholar
Mascalzoni, D. et al. Balancing scientific interests and the rights of participants in designing a recall by genotype study. Eur. J. Hum. Genet. 29, 1146–1157 (2021). This article describes the best practices and policies for recall-by-genotype studies.
Google Scholar
Tremblay, K. et al. The Biobanque quebecoise de la COVID-19 (BQC19)-A cohort to prospectively study the clinical and biological determinants of COVID-19 clinical trajectories. PLoS ONE 16, e0245031 (2021).
Google Scholar
Mooser, V. & Currat, C. The Lausanne Institutional Biobank: a new resource to catalyse research in personalised medicine and pharmaceutical sciences. Swiss Med. Wkly 144, w14033 (2014).
Google Scholar
Maurer, F. et al. Identification and molecular characterisation of Lausanne Institutional Biobank participants with familial hypercholesterolaemia—a proof-of-concept study. Swiss Med. Wkly 146, w14326 (2016).
Google Scholar
Bochud, M., Currat, C., Chapatte, L., Roth, C. & Mooser, V. High participation rate among 25,721 patients with broad age range in a hospital-based research project involving whole-genome sequencing—the Lausanne Institutional Biobank. Swiss Med. Wkly 147, w14528 (2017).
Google Scholar
Mabuchi, H. et al. Effect of an inhibitor of 3-hydroxy-3-methyglutaryl coenzyme A reductase on serum lipoproteins and ubiquinone-10-levels in patients with familial hypercholesterolemia. N. Engl. J. Med. 305, 478–482 (1981).
Google Scholar
Ramsey, B. W. et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N. Engl. J. Med. 365, 1663–1672 (2011).
Google Scholar
Chapman, P. B. et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 364, 2507–2516 (2011).
Google Scholar
Mead, S. et al. Clinical trial simulations based on genetic stratification and the natural history of a functional outcome measure in Creutzfeldt–Jakob disease. JAMA Neurol. 73, 447–455 (2016).
Google Scholar
van Bokhoven, P. et al. The Alzheimer’s disease drug development landscape. Alzheimers Res. Ther. 13, 186 (2021).
Google Scholar
Lopes Alves, I. et al. Strategies to reduce sample sizes in Alzheimer’s disease primary and secondary prevention trials using longitudinal amyloid PET imaging. Alzheimers Res. Ther. 13, 82 (2021).
Google Scholar
Fahed, A. C., Philippakis, A. A. & Khera, A. V. The potential of polygenic scores to improve cost and efficiency of clinical trials. Nat. Commun. 13, 2922 (2022).
Google Scholar
Damask, A. et al. Patients with high genome-wide polygenic risk scores for coronary artery disease may receive greater clinical benefit from alirocumab treatment in the ODYSSEY OUTCOMES trial. Circulation 141, 624–636 (2020).
Google Scholar
Marston, N. A. et al. Predicting benefit from evolocumab therapy in patients with atherosclerotic disease using a genetic risk score: results from the FOURIER trial. Circulation 141, 616–623 (2020). These two independent articles (refs. 142,143) show that patients with a high polygenic risk score for coronary artery disease benefit most from PCSK9 inhibition, suggesting that the selection of participants based on their genomic profile may be useful in early trials.
Google Scholar
Roden, D. M. et al. Benefit of preemptive pharmacogenetic information on clinical outcome. Clin. Pharmacol. Ther. 103, 787–794 (2018).
Google Scholar
Petrović, J., Pešić, V. & Lauschke, V. M. Frequencies of clinically important CYP2C19 and CYP2D6 alleles are graded across Europe. Eur J Hum Genet 28, 88–94 (2020).
Google Scholar
US Department of Health and Human Services et al. Clinical Pharmacogenomics: Premarket Evaluation in Early-Phase Clinical Studies and Recommendations for Labeling https://www.fda.gov/files/drugs/published/Clinical-Pharmacogenomics–Premarket-Evaluation-in-Early-Phase-Clinical-Studies-and-Recommendations-for-Labeling.pdf (FDA, 2013).
Government Chief Scientific Adviser. Genomics Beyond Health https://www.gov.uk/government/publications/genomics-beyond-health (Government Office for Science, 2022).